Company intelligence / Profile preview

SaudiBio

Riyadh, Eastern Province, Saudi Arabia

Ownership: Private
Employees: ~100
Development stage: Other

Overview

SaudiBio is the first and only biotechnology manufacturing facility in Saudi Arabia, established in 2010. It specializes in manufacturing recombinant human insulin, hemophilia products, and biosimilars for oncology and rare diseases. The company operates a state-of-the-art, GMP-certified facility and began producing insulin through a technology transfer partnership with Novo Nordisk. In 2023, SaudiBio was acquired by Lifera to further scale local biopharmaceutical manufacturing.

Therapeutic areas: OncologyHematologyEndocrinologyRare Diseases
Modalities: BiologicRecombinant protein
Industry: Biotech

Partnerships

Novo Nordisk

Beyond the preview

Go deeper on SaudiBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SaudiBio.

Explore the full profile